BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

R3421: Phase II data

Top-line data from a double-blind, placebo-controlled Phase II trial in 87 patients showed that 20, 40 and 80 mg once-daily oral BCX4208 alone and in combination with 100, 200 or 300 mg oral allopurinol met the primary endpoint of producing a dose-dependent reduction in mean sUA concentrations from baseline to day 21....

Read the full 238 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >